Cabaletta Bio Inc. CABA
$2.92
▲ +0.00% 24H
About
Cabaletta Bio Inc. is a clinical-stage biotechnology company specializing in engineered T cell therapies for B cell–mediated autoimmune diseases. The company focuses on leveraging its proprietary CABA platform, which includes two main approaches: CARTA, or chimeric antigen receptor T cells for autoimmunity, and CAART, …
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees156
TickerCABA
Statistics
Market Cap$324.5M
Revenue (TTM)$0
Net Income-$167.9M
Net Margin—
EPS$-2.10
P/E-1.44
P/S—
P/B3.24
EV/EBITDA-2.28
ROE-156.0%
Dividend Yield—
Price$2.92
Data: Twelve Data · Revenue = mcap / P/S